Stock Screener App

Frei -

Installieren

0.5927

1.31% -0.0078

Citius Pharmaceuticals Inc (CTXR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CTXR? Forum Prognose Aktiensplit

Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten

Citius Pharmaceuticals stock stabilizes as investors look to next data catalysts - AD HOC NEWS

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire

Citius Pharmaceuticals Inc. Warrant (CTXRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Citius Pharmaceuticals Inc. Warrant (CTXRW) Key Financial Ratios – Valuation, Profitability & More - Value Research

CTXR Should I Buy - Intellectia AI

CTXR Stock Price, Quote & Chart - ChartMill

Citius Pharmaceuticals Inc. (CTXR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Citius (CTXR) Earnings Report: Reported EPS Misses Expectations in the Latest Reading; Price Reaction: Shares Move 0.07% Higher in the Current UpdateFinal Results - vinanet.vn

Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Nasdaq gives Citius (NASDAQ: CTXR) more time before $1 delisting risk - Stock Titan

H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com - Investing.com South Africa

Citius (CTXR) Market-Day Review: Finishes 1.78% Higher at $0.57 in the Latest Session; Key Levels: the Near-Term Reference Band Stretches From $0.54 to $0.60 in the Available RecordWMA Signal - vinanet.vn

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - finance.yahoo.com

Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Clinical Focus Checkpoint Mean? - Kalkine Media

Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - Kalkine Media

Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus

CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% While Stock Gains 3.0%Analyst Earnings Estimate - vinanet.vn

Citius Pharmaceuticals (CTXR) Gains 3% to $0.76 as Buyers Defend SupportBull Pennant - dars.gov.et

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - The AI Journal

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Citius Oncology, Inc. Announces Appointment of Jonathan Peri, Ph.D., J.D., as Independent Director, Effective August 10, 2026 - marketscreener.com

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan

CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Citius Oncology appoints Jonathan Peri to board of directors - Investing.com

Citius Pharmaceuticals (CTXR) Edges Higher by 1.92%, Maintaining Position Above Key Support at $0.69TWAP Entry - vinanet.vn

BREAKING: THE PRINTING HAS STARTED! Robert De Niro (xWXxQcdGpe) - Mshale

CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% as Shares Rise 6.23%Banking Earnings Report - vinanet.vn

Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ

Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - Morningstar

Citius Pharmaceuticals (CTXR) Advances 5.7% to $0.63; Key Resistance at $0.66 in FocusGamma Flip Level - vinanet.vn

Citius Pharmaceuticals (CTXR) Tumbles 9.81% to $0.57 as Biotech Stock Approaches Critical SupportTake Profit Levels - vinanet.vn

CTXR Q4 2025 Earnings: Wider-than-Expected Loss Met with Positive Stock ReactionOne-Time Gain Impact - vinanet.vn

Citius Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CTXR - TradingView

Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

CTXR|Citius Pharmaceuticals Inc|Price:0.738|Chg%:-0.027 - TradingKey

Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Citius Pharmaceuticals Inc (CTXR) Institutional Confidence - TradingKey

Citius Pharmaceuticals Inc (CTXR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

TradingKey - TradingKey

CTXR|Citius Pharmaceuticals Inc|Price:0.682|Chg%:+0.040 - TradingKey

Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Citius Pharmaceuticals (CTXR) Slips 2%, Hovers Above Key Support at $0.49Retail Sentiment - vinanet.vn

CTXR Q4 2025 Earnings: Wider-than-Expected Loss Highlights Clinical Stage ChallengesGuidance Update - vinanet.vn

Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr

Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com Nigeria

Citius Oncology expands sales team for LYMPHIR launch - Investing.com

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Morningstar

RPRX

$60.18

0.69%

INSM

$129.33

3.67%

ROIV

$41.77

0.78%

ALNY

$255.60

1.73%

ONC

$350.10

0.47%

RVMD

$209.70

1.11%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters